Objective: To determine the influence of surgical site infection (SSI) on the median disease-free interval (DFI) and median survival time (MST) in dogs after amputation in the curative-intent treatment of appendicular osteosarcoma (OSA). Study design: Multi-institutional retrospective cohort study. Animals: Fifteen dogs with OSA and SSI, and 134 dogs with OSA and no SSI. Methods: Medical records were reviewed, and dogs were included if the following criteria were met: histologic confirmation of OSA, no evidence of metastasis, ≥1 chemotherapy treatment, and available follow-up data. We used the definition of SSI from the Centers for Disease Control and Prevention. Kaplan-Meier estimates of median DFI and MST for the SSI and non-SSI groups were compared by logrank test. Univariate and multivariate Cox proportional hazard regression analysis was evaluated for associations with DFI and survival. Results: The median DFI and MST of all OSA dogs were 236 days (95% CI, 181-283) and 283 days (95% CI 237-355), respectively. The median DFI of dogs with SSI (292 days) did not differ from that of dogs without SSI (224 days, P = .156). The MST of dogs with SSI (292 days) did not differ from that of dogs without SSI (280 days, P = .417). Failure to complete chemotherapy was associated with decreased DFI and survival (P < .001). Adjustments for chemotherapy completion found no effect of SSI on survival. Conclusion: SSI did not influence the survival of dogs with appendicular OSA treated with amputation and curative-intent treatment. Clinical significance: The extended survival associated with SSI after limb-spare surgery for OSA does not appear to be present after amputation. Interactions between the canine immune system and OSA warrant additional study.
between the start of curative-intent treatment and the diagnosis of metastatic disease, varies between 137 and 425 days. [3] [4] [5] [6] [7] [8] The median survival time (MST) reported with curativeintent treatment ranges between 258 days and 18 months. [3] [4] [5] [6] [7] [8] [9] [10] [11] Clinical factors associated with individual dog survival include tumor location, elevated serum alkaline phosphatase (ALP), increasing body weight, and evidence of metastasis at the time of diagnosis. [12] [13] [14] [15] Limb-sparing surgery provides an alternative option for local tumor control. The most common technique involves resection of OSA at the distal radius and reconstruction with a metal endoprothesis. [16] [17] [18] [19] [20] Curative-intent treatment of OSA with limb-sparing surgery leads to MST comparable to that of amputation (289-430 days) except in cases with a diagnosis of a surgical site infection (SSI). 17, 18 Multiple independent studies have identified a significant increase in MST associated with the diagnosis of SSI after limb-sparing surgery. 17, 20, 21 Although the mechanism by which SSI prolongs MST has yet to be fully elucidated, systemic activation of the innate immune system and associated antitumor activity has been proposed. 22, 23 Fluoroquinolone antibiotic therapy used in the treatment of SSI may also play a role in prolonging survival. 24, 25 SSI is diagnosed in up to 68% of cases after limb-sparing surgery, whereas SSI is diagnosed in up to 12.8% cases after amputation. 20, 26 The effect of SSI on MST in the curativeintent treatment of OSA with amputation is unknown, justifying clinical investigation. The objective of this study was to determine the influence of SSI after limb amputation on the median DFI and MST of dogs undergoing curative-intent treatment of canine appendicular OSA. We hypothesized that dogs treated by amputation and chemotherapy that had a diagnosis of SSI would have a significantly prolonged median DFI and MST compared with similarly treated dogs that did not have a diagnosis of SSI.
| MATERIALS AND METHODS

| Case selection
The research proposal for this multi-institutional retrospective study was reviewed and approved by the Veterinary Society of Surgical Oncology (VSSO) research committee. Request for study participation was sent to VSSO members via an email list-serve. Medical records from contributing institutions were searched between 2004 and 2016 for dogs with a diagnosis of appendicular OSA that had been treated by amputation and chemotherapy. Inclusion criteria mandated a histologic diagnosis of OSA, no evidence of metastasis based on a minimum diagnostic of 3-view thoracic radiography or other advanced imaging, and ≥1 chemotherapy treatment indicating curative intent. Dogs were excluded when there was no evaluation for metastatic disease prior to surgery, evidence of metastasis was documented (including regional lymph node metastasis), or lack of available followup data.
| Data collection
Data retrieved from the medical records included patient signalment; body weight; tumor location; results of preoperative diagnostic imaging; preoperative serum ALP; preoperative lymphocyte and monocyte counts; histopathology report; surgery report; diagnosis of SSI; initial chemotherapy protocol; completion of chemotherapy; the date and location of first documented metastasis; and the date and cause of death or, if alive or lost to follow-up, the date of last contact. Diagnosis of SSI was based on clinical criteria defined by the Centers for Disease Control and Prevention (Table 1) . 27 Data recorded with each SSI included the date of diagnosis, classification (superficial, deep, organ/space), culture results, and treatment. Contributors collected and submitted all case information to the primary author's institution using a standard accrual form. 
| Statistical analysis
A power analysis was performed to determine the ideal number of dogs for inclusion in the SSI and non-SSI groups ( Table 2) . Survival assumptions were made in this power analysis that the non-SSI group would have an MST of 300 days, consistent with typical OSA survival data, and that the SSI group would have an MST of 685 days, which was previously reported for dogs with a diagnosis of SSI after limb-sparing surgery. 17 Sample size calculations were performed with POWER procedure in SAS v9.4 (SAS Institute, Cary, North Carolina), with COXREG statement providing the power for a Cox proportional hazards regression. It was determined that the study should ideally contain ≥20 dogs in the SSI group and ≥100 dogs in the non-SSI group to detect significant differences in MST with ≥80% power. Descriptive categorical data were presented as counts and percentages. Descriptive continuous data were presented as either mean and standard deviation (normally distributed) or median and interquartile range (IQR; nonnormally distributed). Normality was determined by using the ShapiroWilk test. Categorical data (sex, limb, tumor location, chemotherapy protocol, completion of chemotherapy) were compared between the SSI and non-SSI groups by using either a χ 2 or a Fisher's exact test (any cell count < 10).
Continuous data (age, body weight, ALP, lymphocyte, and monocyte counts) were compared by using either a 2-sample t test (normally distributed) or a Mann-Whitney U test (nonnormally distributed). Kaplan-Meier analysis was used to estimate the median DFI and MST with 95% CI for the overall population, SSI group, and non-SSI group. Definitions from a previous study were used for determining individual dog DFI and survival time. 5 The DFI was defined as the number of days from amputation to the date of documented metastasis or suspected metastasis. Metastasis was suspected at the date of death when patients died or were euthanized without evaluation for metastatic disease and the cause of death was unknown or suspicious for disease progression. The DFI was censored at the date of last contact for dogs alive or lost to follow-up without evidence of metastasis or at the date of death for dogs that had a known cause of death unrelated to OSA (ie, gastric dilatation and volvulus). Survival time was defined as the number of days from amputation to the date of death. Dogs that were alive or lost to follow-up were censored at the date of last contact. Dogs with a known cause of death unrelated to OSA or OSA therapy were censored at the date of death. When the cause of death or euthanasia was unknown, then it was always attributed to OSA. KaplanMeier estimates of median DFI and MST were compared by using a log-rank test. A post hoc power analysis was performed for nonsignificant results. One-, 2-, and 3-year survival proportions were also compared. Univariate Cox proportional hazard regression analysis was used to evaluate the overall population for associations with clinical factors (age, body weight, proximal humeral OSA location, distal radial OSA location, ALP, monocyte and lymphocyte count, SSI, and chemotherapy completion) and oncologic outcome (DFI and survival). Associations were expressed as hazard ratios (HR) with 95% CI. Multivariate analysis with adjustments was performed on the basis of associations identified during univariate analysis. Significance for all tests was set at P < .05. Analysis was performed in SAS v9.4 (SAS Institute). forequarter amputation was performed in all cases. The pelvic limb was affected in 64 (43%) dogs, and amputation techniques consisted of coxofemoral disarticulation (n = 45), proximal femoral ostectomy (n = 15), or hemipelvectomy (n = 4). Tumor location included the proximal humerus (n = 42, 28.2%), distal radius (n = 38, 25.5%), proximal tibia (n = 22, 14.8%), distal femur (n = 19, 12.8%), and other locations of the appendicular skeleton (n = 28, 18.8%). Preoperative diagnostic imaging for metastasis consisted of thoracic radiography (n = 143, 96%), nuclear scintigraphy (n = 28, 18.8%), and thoracic computed tomography (CT); n = 21, 14.1%). Evidence of metastatic disease was not identified in any case, as dictated by study inclusion criteria.
Chemotherapy was performed in all dogs as part of curative-intent treatment. The most common chemotherapy protocol was single-agent carboplatin (n = 78, 52.3%), followed by alternating carboplatin and doxorubicin (n = 54, 36.2%), single-agent doxorubicin (n = 12, 8.1%), and protocols containing cisplatin (n = 5, 3.4%). In total, 108 dogs (72.5%) completed their prescribed injectable chemotherapy protocol. Metronomic chemotherapy was prescribed after completion of the injectable protocol in 20 dogs. Rescue chemotherapy after the diagnosis of metastatic disease was performed in 13 dogs.
Among the 149 dogs, 15 were included in the SSI group, and 134 were included in the non-SSI group. The median time of SSI diagnosis was 10 days (IQR, 6-14) after amputation. Eleven (73.3%) cases were confirmed by positive bacterial culture (Table 3) . Classification of SSI included superficial (n = 9) and deep (n = 6). The SSI was located at the amputation site in all but 1 dog. In that 1 case, SSI occurred within 30 days at a vascular access port that was placed concurrently at the time of amputation. Resolution of SSI was achieved within 30 days of diagnosis in all cases. Antimicrobial therapies administered for SSI treatment included amoxicillin/clavulanic acid (n = 7), amoxicillin (n = 3), ciprofloxacin (n = 3), enrofloxacin (n = 2), cephalexin (n = 2), cefpodoxime, and amikacin. Five cases received more than 1 antimicrobial therapy. Surgical wound management (ie, abscess drainage, debridement, closure) was also performed in 6 cases.
Patient and tumor characteristics were compared between the SSI group and the non-SSI group (Table 4) . The only significant difference between the SSI and non-SSI groups was a greater median body weight for dogs within the SSI group (P = .024). At the time of last follow-up, 126 dogs were deceased. The overall population median DFI and MST were 236 days (95% CI, 181-283) and 283 days (95% CI, 237-355), respectively. Twenty-five dogs were censored in DFI analysis (6 in SSI group, 19 in non-SSI group). The median DFI for the SSI and the non-SSI groups were 292 days (95% CI, 98-) and 224 days (95% CI, 168-282), respectively ( Figure 1 ). There was no difference in median DFI between groups (P = .156). The upper 95% confidence limit for the SSI group could not be determined due to censorship. Twentyeight dogs were censored in survival analysis. Thirteen dogs were still alive (3 in SSI group, 10 in non-SSI group), 10 dogs were lost to follow-up (1 in SSI group, 9 in non-SSI group), and 5 dogs died of a cause unrelated to OSA (1 in SSI group, 4 in non-SSI). The MST for the SSI group and the non-SSI groups were 292 days (95% CI, 88-856) and 280 days (95% CI, 232-355), respectively (Figure 2 ). There was no difference in MST between groups (P = .417). One-, 2-, and 3-year survival proportions were similar between groups ( Table 5 ). The DFI was strongly correlated to survival time in each group (Figure 3) .
Univariate Cox proportional hazard analysis found failure to complete chemotherapy associated with an increased risk for disease progression (P < .001; HR, 3.866; 95% CI, 2.591-5.769) and death (P < .001; HR, 3.416; 95% CI, 2.297-5.078; Table 6 ). Multivariate Cox proportional hazard analysis evaluating for the effects of SSI while adjusting for chemotherapy completion found no effect of SSI on either DFI or survival.
| DISCUSSION
In this study, SSI after limb amputation did not prolong the median DFI or MST in the curative-intent treatment of canine appendicular OSA. We therefore reject our initial hypothesis. To the best of the authors' knowledge, this is the first published study to evaluate the effect of SSI on oncologic outcome after amputation for appendicular OSA. The population in this study included predominately old, largeto-giant breed dogs with an overall median DFI of 236 days and an overall MST of 283 days, in line with previous reports.
2,3,6-8 The only association with oncologic outcome in this study was a higher risk for disease progression and death when failing to complete the initial chemotherapy protocol. This is inherently biased because failure to complete chemotherapy is often the result of either the development of early metastatic disease or adverse events prompting owners to discontinue therapy. In a multivariate analysis with adjustments for chemotherapy completion, SSI still had no effect on DFI or survival. The lack of influence of SSI on survival in our study likely reflects clinical differences in SSI between amputation and limb-sparing surgery. Characterization of SSI after amputation was a mixture of superficial and deep infections, all of which developed in the perioperative period, and resolved within 30 days of initiating treatment. By contrast, SSI after limb-sparing surgery are often deep, develop beyond the initial perioperative period, and may persist for months after diagnosis. 2, 20 The immunologic mechanism proposed to explain the prolonged survival with SSI partially relies on an inhibition of metastatic growth by natural killer cells, monocytes, and tumor associated macrophages. 22, 23 In a mouse model, it was found not only that chronic osteomyelitis inhibited OSA tumor growth effectively but also that depletion of either natural killer cells or monocytes reversed this antitumoral effect. 22 The chronicity of SSI appears key to sustaining a low-level of systemic inflammation. The limited duration of SSI after amputation may not provide the adequate time that is required to stimulate these innate immune responses. An additional consideration may be the proximity of SSI to potential residual OSA cells after a marginal limb-spare excision, which may enhance the antitumor immune response. These considerations lead us to conclude that comparable median DFI and MST between cases with and without SSI after amputation are plausible. Measurement and comparison of markers of innate immunity, such as natural killer cells, during various phases of SSI after amputation and limb-sparing surgery are required to validate this theory. Bacterial cultures of SSI after limb-sparing surgery often yield mixed bacterial populations, with isolates similar to those reported in the present study. 17, 20 The duration of SSI is probably more relevant than the specific bacteria involved. Antibiotic treatment selection may also play a role in prolonging survival. Fluoroquinolones have been found to inhibit in vitro growth of OSA cell lines as well as potentiating the activity of chemotherapy against OSA. 24, 25 Fluoroquinolones were administered in only 5 of the 15 SSI cases in this study and were prescribed for short duration (<30 days). By comparison, Lascelles et al 20 noted 24 of 32 dogs receiving fluoroquinolone antibiotic therapy in their report documenting a survival advantage with SSI after limb-sparing surgery. Evaluation of any effect that fluoroquinolone therapy may have on survival is beyond the scope of the present study. Clinical research into the effects of fluoroquinolone therapy during OSA treatment is required to determine whether their use makes a significant contribution to prolonging survival. This study had limitations inherent to the multiinstitutional retrospective design, including a lack of randomization and standardization, potential for institutional bias, and a reliance on medical record accuracy. As expected, DFI and survival time were correlated in this study. The use of median DFI as the primary outcome measure has been suggested as more accurate in prospective studies evaluating the effects of disease treatment (ie, chemotherapy). 5 For the purposes of a retrospective study, survival time in our opinion is a better outcome measure because it is unambiguously defined, whereas DFI is E94reported at the documented date of detection and is not necessarily representative of the actual date of disease progression. Prospective studies are better suited for standardizing the evaluation of disease progression. The final sample size of the SSI group could be considered a study limitation because we were unable to achieve our ideal sample size of 20 dogs. The SSI group included 15 dogs; however, the MST of dogs with and without SSI in the present study were similar at 292 and 280 days, respectively. In comparison, Liptak et al 17 reported an MST of 685 days after SSI in a population of 11 dogs with limbsparing surgery, more than double the MST of 289 days for dogs without SSI in that same study. A post hoc power analysis revealed that samples of 443 and 1436 dogs would have been required to report significance for the relatively small differences in our median DFI and MST, respectively. It is improbable that 5 additional SSI cases (to achieve 20 total) would have altered our study's conclusion. Despite the lack of randomization, baseline data for the SSI and non-SSI groups were similar, except for a greater median body weight for dogs with a diagnosis of SSI. This finding was not surprising because greater body weights have been associated with increased risk of developing SSI in veterinary orthopedics. [28] [29] [30] Some studies on OSA have associated greater body weights with decreased survival times; however, this was not found in our analysis. 3, 15, 20 It is unlikely that the difference in body weight reported here affected our results. Preoperative screening for metastasis varied between institutions. Three-view thoracic radiography has been the minimum requirement for metastatic screening in multiple studies of appendicular OSA. 3, 4, 6, 11 Three-view thoracic radiography was the only diagnostic test to evaluate for metastatic disease in 110 (73.8%) of the cases in this study. Thoracic CT and nuclear scintigraphy are more sensitive for detecting metastatic disease, but their use can be limited by institutional availability and cost. [31] [32] [33] [34] Therefore, the potential for undocumented metastatic disease at the time of amputation in at least 1 case cannot be excluded. Chemotherapy protocols also varied by institutions. Currently, no specific protocol has been shown to improve survival significantly compared with any other. 3 A single-agent carboplatin protocol did significantly prolong DFI in comparison to an alternating carboplatin and doxorubicin protocol in a prospective study and was associated with fewer adverse events in a separate retrospective study. 3, 5 Single-agent carboplatin was the most common protocol used in both the SSI and non-SSI groups. In addition, metronomic and/or rescue therapy was prescribed in 33 (22.2%) cases. The addition of metronomic chemotherapy or rescue therapy has not been shown to prolong survival beyond that noted with the initial injectable chemotherapy protocol. [35] [36] [37] This lack of evidence prompts us to propose that the inclusion of cases that had these additional therapies was unlikely to affect our results.
Several clinical factors previously associated with prognosis, such as OSA of the proximal humerus and elevated ALP, did not correlate to either DFI or MST in this study. 12 Because of the retrospective nature of this report, ALP values were not available for all cases, which may explain that particular finding. Type II error must also be considered. There were also factors not included within our analysis, such as tumor grade or mitotic index, because of discrepancies in histopathology reports between various institutions, although the predictive value of tumor grade can be considered questionable. 38 In conclusion, the diagnosis of SSI after amputation in the curative-intent treatment of appendicular OSA was not associated with prolonged median DFI or MST in this retrospective study. Additional investigation into the complex interactions of the canine immune system, SSI duration, and metastatic OSA are warranted. Elucidating the exact mechanism by which SSI prolongs survival may improve treatment options and clinical outcomes for dogs with a diagnosis of appendicular OSA.
